ANACOR PHARMS INC
PharmaANACOR PHARMS INC is a pharmaceutical company focused on Dermatology. Key products include EUCRISA.
ANACOR PHARMS INC's Key Drugs
ANACOR PHARMS INC's core commercial portfolio centers on EUCRISA, spanning Dermatology — its most strategically important drugs approved in the last 15 years.
ANACOR PHARMS INC's Recent FDA Approvals
New NDA/BLA approvals for ANACOR PHARMS INC over the last two years — novel drugs only, excluding generics and label supplements.
ANACOR PHARMS INC's Therapeutic Areas
ANACOR PHARMS INC's approved drugs and pipeline span 1 therapeutic area, led by Dermatology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ANACOR PHARMS INC's Top Competitors
ANACOR PHARMS INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ANACOR PHARMS INC Pipeline Snapshot
Active clinical trials for ANACOR PHARMS INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • EUCRISA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Dermatology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling